Hims & Hers Surges on Novo Obesity Deal That Ends Public Feud Hims & Hers Health Inc. saw its stock price rise sharply after Novo Nordisk A/S agreed to end its public dispute with the company through a new partnership. The deal involves Novo Nordisk’s weight-loss medications being sold on the Hims platform, marking a resolution to their ongoing conflict. According to a source familiar with the matter, the two companies plan to formally announce the partnership on Monday. This agreement follows a similar deal from last year, which Novo abruptly canceled after Hims continued marketing and selling generic versions of Novo’s drugs. The feud had drawn significant attention, with both companies accusing each other of unfair practices. The new partnership is expected to address these tensions by allowing Novo to distribute its obesity treatments through Hims’s digital health platform. This move could expand access to weight-loss medications for patients while providing Hims with additional revenue streams. Analysts suggest the deal reflects a broader trend of pharmaceutical companies seeking to leverage digital health platforms to reach consumers directly. The resolution of the public feud has also bolstered investor confidence in Hims & Hers, contributing to its stock surge. The company has long positioned itself as a leader in the digital wellness space, offering products ranging from hair loss treatments to sexual health solutions. With the addition of Novo’s obesity drugs, Hims aims to strengthen its portfolio and compete more effectively in the crowded health tech market. The partnership underscores the growing importance of digital platforms in healthcare, as companies seek to bypass traditional distribution channels and engage consumers directly.#hims_hers #novonordisk #hims_hers_health_inc #hims #novonordisk_as
Novo Nordisk ends legal proceedings against Hims & Hers Hims & Hers shares surged after Novo Nordisk announced it would drop its patent infringement lawsuit against the telehealth provider. The decision followed an agreement between the two companies, which includes Hims offering Novo’s branded weight-loss drugs at the same price as other telehealth platforms and ceasing to advertise compounded GLP-1 drugs. Novo Nordisk CEO Mike Doustdar stated the legal case would be dropped, though the company reserved the right to revisit it if necessary. The agreement also involves Hims selling injectable and oral semaglutide, marketed as Ozempic and Wegovy, through its platform at prices comparable to other telehealth services. Hims will no longer promote compounded versions of GLP-1 drugs, which are unapproved by the FDA. The move comes after Novo accused Hims of selling counterfeit versions of Wegovy at a significantly lower price, which sparked backlash from both the company and the U.S. Food and Drug Administration. Hims’ shares rose over 40% in early trading, while Novo’s stock gained 2.1%. The FDA’s commissioner, Marty Makary, praised the agreement, emphasizing that Hims will provide affordable, FDA-approved medications and limit compounded drugs to rare cases. Makary noted that Hims’ shift away from unapproved compounded products aligns with regulatory efforts to curb illegal compounding practices. The dispute began in February when Novo sued Hims for selling a copycat version of Wegovy at $49, far below the branded price. Hims quickly halted the sale after pressure from Novo and the FDA, which warned of potential legal violations. The FDA has since pledged to take action against compounding pharmacies and referred Hims to the Department of Justice for further review.#hims_hers #novonordisk #marty_makary #semaglutide #zepbound
